| scholarly article | Q13442814 |
| P2093 | author name string | Maria F Lopes-Virella | |
| Gabriel Virella | |||
| P2860 | cites work | CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs | Q24304430 |
| CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer | Q24642646 | ||
| A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages | Q28634082 | ||
| CD36 is a receptor for oxidized low density lipoprotein | Q28678362 | ||
| Cellular survival: a play in three Akts | Q29547806 | ||
| Oxidative Stress and Diabetic Complications | Q29615423 | ||
| Signal transducer and activator of transcription-1 is critical for apoptosis in macrophages subjected to endoplasmic reticulum stress in vitro and in advanced atherosclerotic lesions in vivo. | Q30481584 | ||
| Heat shock protein 70B' (HSP70B') expression and release in response to human oxidized low density lipoprotein immune complexes in macrophages | Q30494525 | ||
| Development of capture assays for different modifications of human low-density lipoprotein | Q33593614 | ||
| Clinical significance of the humoral immune response to modified LDL. | Q33598770 | ||
| Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress | Q33641499 | ||
| Fcgamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway | Q33662418 | ||
| Differential Trafficking of Oxidized LDL and Oxidized LDL Immune Complexes in Macrophages: Impact on Oxidative Stress | Q33686991 | ||
| Sphingosine kinase regulates oxidized low density lipoprotein-mediated calcium oscillations and macrophage survival | Q33784652 | ||
| Endothelial dysfunction, oxidation of low-density lipoprotein, and cardiovascular disease | Q33802499 | ||
| The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia | Q34070759 | ||
| Minimally modified low density lipoprotein stimulates monocyte endothelial interactions | Q34248823 | ||
| Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques | Q34327535 | ||
| Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy | Q34388076 | ||
| Pathophysiology of coronary artery disease | Q34429470 | ||
| Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes | Q34527165 | ||
| Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes | Q34542912 | ||
| The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study | Q34557344 | ||
| Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes | Q34586849 | ||
| Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis | Q34620005 | ||
| Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion | Q34650648 | ||
| Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk | Q34890672 | ||
| Innate immunity and monocyte-macrophage activation in atherosclerosis. | Q34980214 | ||
| Lipoprotein autoantibodies: measurement and significance | Q35140009 | ||
| The role of immune and inflammatory processes in the development of macrovascular disease in diabetes | Q35212965 | ||
| Isolation and characterization of human antioxidized LDL autoantibodies | Q71055886 | ||
| Diagnostic value of immune cholesterol as a marker for atherosclerosis | Q71372364 | ||
| Lipoprotein oxidation and lipoprotein-induced cytotoxicity | Q71725492 | ||
| Aggregation as well as chemical modification of LDL during oxidation is responsible for poor processing in macrophages | Q72663124 | ||
| Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells | Q72828877 | ||
| Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus | Q73134572 | ||
| Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein. Influences of degree of oxidation and location of oxidized LDL | Q73342684 | ||
| Oxidized low density lipoprotein inhibits macrophage apoptosis by blocking ceramide generation, thereby maintaining protein kinase B activation and Bcl-XL levels | Q73401195 | ||
| Plasma MMP-9 - a marker of carotid plaque instability | Q73424056 | ||
| Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies | Q73708419 | ||
| Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes | Q73922473 | ||
| Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques | Q77976688 | ||
| Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies | Q80349440 | ||
| OxLDL-IgG immune complexes induce survival of human monocytes | Q82063625 | ||
| Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells | Q35553734 | ||
| Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells | Q35822759 | ||
| High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes | Q35976427 | ||
| High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes | Q36318280 | ||
| Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages | Q36364861 | ||
| Biomarkers of atherosclerotic plaque instability and rupture | Q36643429 | ||
| Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy | Q37012519 | ||
| Mechanisms and consequences of macrophage apoptosis in atherosclerosis | Q37308942 | ||
| Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake | Q37340933 | ||
| Protein tyrosine kinase, syk: a key player in phagocytic cells | Q37362792 | ||
| Adaptive immunity and atherosclerosis | Q37563746 | ||
| Innate immune signals in atherosclerosis | Q37594311 | ||
| Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis | Q37705133 | ||
| Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. | Q37779008 | ||
| Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae | Q37875278 | ||
| Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of dia | Q38292287 | ||
| Anti-OxLDL IgG blocks OxLDL interaction with CD36, but promotes FcgammaR, CD32A-dependent inflammatory cell adhesion | Q40212791 | ||
| OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages | Q40262380 | ||
| Injury to human endothelial cells in culture induced by low density lipoproteins | Q40283149 | ||
| Atherosclerosis, diabetes and obesity | Q40308336 | ||
| Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease | Q40344004 | ||
| Oxidized lipoproteins, altered cell function and atherosclerosis | Q40557363 | ||
| Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease | Q40596987 | ||
| Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. | Q40730866 | ||
| The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor | Q41071447 | ||
| Multiple receptors for modified low density lipoproteins in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized low density lipoproteins | Q41825522 | ||
| Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies | Q41941628 | ||
| Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins | Q42083643 | ||
| Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells | Q43193872 | ||
| Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy | Q44219630 | ||
| RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. | Q44228474 | ||
| Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. | Q44250487 | ||
| A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. | Q45945242 | ||
| Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. | Q46150836 | ||
| Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. | Q46326610 | ||
| Enhanced macrophage degradation of biologically modified low density lipoprotein. | Q46543466 | ||
| Oxidized LDL immune complexes induce release of sphingosine kinase in human U937 monocytic cells. | Q46975208 | ||
| Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes | Q46986032 | ||
| Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. | Q50862861 | ||
| Multiple Biological Predictors for Vulnerable Carotid Lesions | Q59161764 | ||
| Different apolipoprotein B breakdown patterns in models of oxidized low density lipoprotein | Q59704191 | ||
| Lipoprotein immune complexes as markers of atherosclerosis | Q67880615 | ||
| Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages | Q69662448 | ||
| Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products | Q70328162 | ||
| Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine | Q70511090 | ||
| Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers | Q70779544 | ||
| P304 | page(s) | 76 | |
| P577 | publication date | 2012-06-15 | |
| P1433 | published in | Frontiers in Endocrinology | Q27723680 |
| P1476 | title | The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes | |
| P478 | volume | 3 |
| Q37143813 | Extravascular modified lipoproteins: a role in the propagation of diabetic retinopathy in a mouse model of type 1 diabetes. |
| Q37261617 | Immune mechanisms in atherosclerosis, especially in diabetes type 2 |
| Q28393186 | Impact of cyanidin-3-glucoside on glycated LDL-induced NADPH oxidase activation, mitochondrial dysfunction and cell viability in cultured vascular endothelial cells |
| Q33942486 | Modified Lipoproteins in Diabetic Retinopathy: A Local Action in the Retina |
| Q37254899 | Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes |
| Q37372290 | Proteomic Insight Reveals Elevated Levels of Albumin in Circulating Immune Complexes in Diabetic Plasma |
| Q34434803 | Relationship between oxidized low-density lipoprotein antibodies and obesity in different glycemic situations |
| Q26830676 | Role of regulatory micro RNAs in type 2 diabetes mellitus-related inflammation |
| Q41872168 | The role of the immune system in the pathogenesis of diabetic complications |
Search more.